136 related articles for article (PubMed ID: 22509863)
1. Avoiding adverse events with dabigatran by careful selection of eligible patients.
Baker RI; Harper P; McLintock C
Med J Aust; 2012 Apr; 196(7):431-2. PubMed ID: 22509863
[No Abstract] [Full Text] [Related]
2. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Panchenko EP
Kardiologiia; 2011; 51(11):83-90. PubMed ID: 22117775
[No Abstract] [Full Text] [Related]
3. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Manotti C;
Thromb Haemost; 2011 Nov; 106(5):868-76. PubMed ID: 21946939
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Shevelev VI; Kanorskiĭ SG
Kardiologiia; 2012; 52(7):56-60. PubMed ID: 22839715
[TBL] [Abstract][Full Text] [Related]
6. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
[TBL] [Abstract][Full Text] [Related]
7. Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Sawaya FJ; Musallam KM; Arnaout S; Rabah A; Sawaya J
Int J Cardiol; 2012 Jan; 154(2):e27-8. PubMed ID: 21624685
[No Abstract] [Full Text] [Related]
8. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Beasley BN; Unger EF; Temple R
N Engl J Med; 2011 May; 364(19):1788-90. PubMed ID: 21488759
[No Abstract] [Full Text] [Related]
9. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
11. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
12. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
13. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Simonsen CZ; Steiner T; Tietze A; Damgaard D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e133-4. PubMed ID: 24103671
[TBL] [Abstract][Full Text] [Related]
14. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Alonso-Coello P; Zhou Q; Guyatt G
Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
16. Dabigatran versus warfarin in patients with mechanical heart valves.
Eikelboom JW; Connolly SJ; Brueckmann M; Granger CB; Kappetein AP; Mack MJ; Blatchford J; Devenny K; Friedman J; Guiver K; Harper R; Khder Y; Lobmeyer MT; Maas H; Voigt JU; Simoons ML; Van de Werf F;
N Engl J Med; 2013 Sep; 369(13):1206-14. PubMed ID: 23991661
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
[TBL] [Abstract][Full Text] [Related]
19. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
20. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Steinberg BA; Holmes DN; Piccini JP; Ansell J; Chang P; Fonarow GC; Gersh B; Mahaffey KW; Kowey PR; Ezekowitz MD; Singer DE; Thomas L; Peterson ED; Hylek EM;
J Am Heart Assoc; 2013 Nov; 2(6):e000535. PubMed ID: 24275632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]